Valuation dashboard for Candel Therapeutics, Inc. (CADL) with P/E N/A, P/B 5.42, EV/EBITDA -7.48 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $11.02, CADL has negative trailing earnings (P/E not meaningful) and an ROE of -89.38%. Market capitalisation stands at $807M.
Balance sheet quality for CADL: current ratio of 13.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 5.42 |
| EV / EBITDA | -7.48 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $2.20 |
| vs Current Price | -80.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CADL | Candel Therapeutics, Inc. | $807M | 5.42 | -89.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $11.02 |
| Market Cap | $807M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -89.38% |
| Return on Invested Capital | -36.74% |
| Return on Assets | -42.53% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALDX · CABA · CAPR · CTNM · EDIT · GNLX · IMMP
Explore sector: Healthcare · Biotechnology
More sections of CADL: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks